SYNTAXES: CABG for Best 10-Year Survival in Multivessel Disease SYNTAXES: CABG for Best 10-Year Survival in Multivessel Disease

Longer-term outcome data from SYNTAX trial give a ' clear mandate ' to expand the role of CABG and to adopt a more cautious indication for PCI in multivessel disease, one expert says.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Cardiology News Source Type: news